TTrialPathMatch Me to Trials
← Back to trials
RecruitingHIV

A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1

Eligible age

18–55 yrs

Accepts

All genders

Locations

7 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This study is testing a lab-made antibody called ePGT121v1-LS that targets a specific part of HIV. Researchers will give it by vein (IV) and under the skin (SC), both on its own and together with two other antibodies, VRC07-523LS and PGDM1400LS, which target different parts of the virus. They will assess safety and side effects, determine the right dose, study how the body processes the drug (pharmacokinetics or PK), and measure how well it neutralizes HIV in the blood (serum neutralizing activity). The expectation is that ePGT121v1-LS, whether given alone or with PGDM1400LS and VRC07-523LS, by IV or SC, will be safe in generally healthy adults and that the antibodies will not interfere with each other when used together. Approximately 83 volunteers in overall good health and without HIV-1 will be enrolled into two parts (A and B). Part A has six groups. In Groups 1-3, participants will get ePGT121v1-LS given by IV at one of three dose levels: 5 mg/kg, 20 mg/kg, or 40 mg/kg. In Groups 4-6, participants will receive three antibodies-first ePGT121v1-LS, then PGDM1400LS and VRC07-523LS-given by IV at two separate visits that are 24 weeks apart. The total study duration for participants in Part A is 48 weeks of scheduled clinic visits. Part B has two groups. In Group 7, people will get ePGT121v1-LS as SC shots at two visits 12 weeks apart. Each visit will give a total of 375 mg, split into three injections of 125 mg each. In Group 8, people will also have two visits 12 weeks apart and will receive three antibodies as SC shots in this order: first ePGT121v1-LS (125 mg), then PGDM1400LS (100 mg), and then VRC07-523LS (100 mg). The total study duration for participants in Part B is 24 weeks of scheduled clinic visits.

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

You may qualify if…

  • ✓ 1. Age 18 to 55 years.
  • ✓ 2. Can visit a participating clinic and is willing to stay in the study for its full duration.
  • ✓ 3. Understands the study and is able and willing to give informed consent.
  • ✓ 4. Agrees not to join another experimental study until the final required clinic visit.
  • ✓ 5. In good overall health based on medical history, physical exam, and screening lab tests.
  • ✓ 6. Willing to receive HIV test results.
  • ✓ 7. Willing to discuss personal risk of getting HIV and to have HIV prevention counseling.
  • ✓ 8. Judged by clinic staff to have a low risk of getting HIV and agrees to avoid higher risk behaviors through the last clinic visit.

You may not qualify if…

  • ✕ 1. Received blood products within 120 days before the first study dose (unless the safety review team approves earlier enrollment).
  • ✕ 2. Took any experimental (investigational) research drug within 30 days before the first study dose.
  • ✕ 3. Weighs less than 35 kg or more than 115 kg.
  • ✕ 4. Plans to join another study using an experimental product, or any study that requires non Network HIV antibody testing, during this study.
  • ✕ 5. Pregnant or breastfeeding.
  • ✕ 6. Previously received an HIV vaccine in a vaccine trial. If a potential participant received placebo/control only, eligibility will be decided case by case by the safety review team.
  • ✕ 7. Received any non HIV vaccine within 14 days before enrollment or plan to get one within 14 days after enrollment. Exception: ACAM2000 smallpox vaccine within 28 days before enrollment (or scab still present if earlier) or planned within 14 days after enrollment.
  • ✕ 8. Received humanized or human monoclonal antibodies (mAbs), whether approved or experimental.

Where it's recruiting

Alabama

Birmingham

California

San Francisco

Georgia

Atlanta

Pennsylvania

Philadelphia

Tennessee

Nashville

Texas

Houston

Source: ClinicalTrials.gov · NCT07390955 · last updated 2026-11-16